Analysis of levels of oxidative stress markers depending on the left ventricular ejection fraction in patients with chronic heart failure

Aim. To study and analyze the levels of oxidative stress (OS) markers (malondialdehyde (MDA), superoxide dismutase (SOD), advanced oxidation protein products (AOPPs)) depending on the left ventricular ejection fraction (LVEF) and functional class (FC) in patients with chronic heart failure (CHF).

Material and methods. We examined 60 somatically healthy individuals and 345 patients with CHF, which were divided into three main groups depending on the LVEF and subgroups depending on FC. The levels of OS markers were determined in blood serum — MDA, SOD and AOPPs.

Results. In the group of patients with preserved LVEF and FC II-IV CHF, levels of MDA and AOPPs were statistically significantly higher, and the SOD level was lower compared to the control group. In the group of patients with moderately reduced and reduced LVEF, the levels of MDA and AOPPs were statistically significantly higher, and SOD activity was lower compared with the control group and the group of patients with CHF and preserved LVEF. In patients with CHF with higher FC, there was a statistically significant increase of MDA and AOPPs levels and decrease of SOD activity. The most pronounced changes in the levels of above-mentioned markers were recorded in patients with reduced LVEF. According to the correlation analysis a direct relationship between the levels of markers of the OS and clinical manifestations of the disease was found.

Conclusion. Changes in levels of MDA, SOD and AOPPs in patients with CHF were detected already in the early stages of the disease compared with the control group. In patients with higher FC CHF and preserved, moderately reduced and reduced LVEF, a statistically significant increase in the levels of MDA and AOPPs and a decrease of SOD activity were observed. The most pronounced changes in the levels of the markers were indicated in patients with reduced LVEF.

1. Mareyev VYu, Fomin VYu, Ageyev FT, et al. Clinical recommendations. Chronic heart failure (CHF). 2017;18(1):3-40. (In Russ.) doi:10.18087/rhfj.20171.2346.

2. Lopatin Y. Heart Failure with Mid-Range Ejection Fraction and How to Treat It. Card Fail Rev. 2018;4(1):9-13. doi:10.15420/cfr.2018:10:1.

3. Wang N, Hales S, Barin E, et al. Characteristics and outcome for heart failure patients with mid-range ejectionfraction. J Cardiovasc Med (Hagerstown). 2018;19(6):297-303. doi:10.2459/JCM.0000000000000653.

4. Palatkina LO, Korneyeva ON, Drapkina OM. Oxidative stress, its role in the pathogenesis of chronic heart failure, and potential methods of correction. Cardiovascular Therapy and Prevention. 2012; 11 (6):91-4. (In Russ.)

5. Shchukin YuV, Seleznev EI, Berezin II, et al. The connection of plazma contents of galectin-3 with markers of oxidative and nitrosylate stresses of patients with chronic cardiac insufficiency. Medical Almanac. 2012;1(20):189-91. (In Russ.)

6. Hu J, Cheng P, Huang GY, et al. Effects of Xin-Ji-Er-Kang on heart failure induced by myocardial infarction: Role of inflammation, oxidative stress and endothelial dysfunction. Phytomedicine. 2018;42:245-57. doi:10.1016/j.phymed.2018.03.036.

7. Sorop O, Heinonen I, van Kranenburg M, et al. Multiple common comorbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress, and myocardial stiffening. Cardiovasc Res. 2018;114(7):954-64. doi:10.1093/cvr/cvy038.

8. Osipova OA, Plaksina KG, Komisov AA, et al. The pathogenetic mechanisms of participation of myocardial extracellular matrix remodeling of the heart in patients with chronic heart failure. Scientific bulletins of the Belgorod State University. Series: Medicine. Pharmacy. 2015;22(219):18-25. (In Russ.)

9. Baranov AP, Strutynskiy AV, Panchenko LF, et al. Peculiarities of vegetative dysfunction, system activity of proinflammatory cytokines and oxidative stress status in patients with chronic heart failure and depressive disorders. Pathogenesis. 2016;14(2):66-70. (In Russ.)

10. Wert KJ, Velez G, Cross MR, et al. Extracellular superoxide dismutase (SOD3) regulates oxidative stress at the vitreoretinal interface. Free Radic Biol Med. 2018;124:408-19. doi:10.1016/j.freeradbiomed.2018.06.024.

11. Maksimova LN, Maksimov ML, Nartsissov YaR, et al. Role of the metabolite therapy for the treatment of chronic heart failure. Rational Pharmacotherapy in Cardiology. 2013;9(5):577-81. (In Russ.)

12. Sairam T, Patel AN, Subrahmanian M, et al. Evidence for a hyper-reductive redox in a sub-set of heart failure patients. J Transl Med. 2018;16(1):130. doi:10.1186/s12967-018-1503-x

13. Liang M, Wang J, Xie C, et al. Increased plasma advanced oxidation protein products is an early marker of endothelial dysfunction in type 2 diabetes patients without albuminuria 2. J Diabetes. 2014;6(5):417-26. doi:10.1111/1753-0407.12134.

14. Ou H, Huang Z, Mo Z, et al. The Characteristics and Roles of Advanced Oxidation Protein Products in Atherosclerosis. CardiovascToxicol. 2017;17(1):1-12. doi:10.1007/s12012-016-9377-8.

15. Yavuzer S, Yavuzer H, Cengiz M, et al. The role of protein oxidation and DNA damage in elderly hypertension. Aging ClinExp Res. 2016;28(4):625-32. doi:10.1007/s40520-015-0464-7.